GlaxoSmithKline plc (LON:GSK)‘s stock had its “hold” rating reissued by analysts at Shore Capital in a report issued on Thursday.

Several other brokerages also recently weighed in on GSK. Beaufort Securities lifted their price objective on shares of GlaxoSmithKline plc from GBX 1,750 ($22.60) to GBX 2,000 ($25.83) and gave the company a “buy” rating in a research report on Thursday, June 1st. Liberum Capital reiterated a “buy” rating and issued a GBX 1,900 ($24.54) price objective on shares of GlaxoSmithKline plc in a research report on Tuesday, June 6th. S&P Global set a GBX 1,500 ($19.37) price objective on shares of GlaxoSmithKline plc and gave the company a “sell” rating in a research report on Tuesday, June 6th. Jefferies Group LLC lifted their price objective on shares of GlaxoSmithKline plc from GBX 1,800 ($23.25) to GBX 1,900 ($24.54) and gave the company a “buy” rating in a research report on Friday, June 16th. Finally, UBS AG set a GBX 1,600 ($20.66) price objective on shares of GlaxoSmithKline plc and gave the company a “neutral” rating in a research report on Friday, June 9th. Four analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of GBX 1,705.90 ($22.03).

Shares of GlaxoSmithKline plc (LON GSK) traded down 1.79% during midday trading on Thursday, hitting GBX 1454.00. 14,085,046 shares of the stock were exchanged. The firm has a 50-day moving average price of GBX 1,507.18 and a 200-day moving average price of GBX 1,610.52. The company’s market cap is GBX 71.07 billion. GlaxoSmithKline plc has a 12-month low of GBX 1,446.50 and a 12-month high of GBX 1,745.56.

TRADEMARK VIOLATION WARNING: “Shore Capital Reaffirms “Hold” Rating for GlaxoSmithKline plc (GSK)” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/09/16/shore-capital-reaffirms-hold-rating-for-glaxosmithkline-plc-gsk.html.

In other news, insider Victoria Whyte sold 4,820 shares of GlaxoSmithKline plc stock in a transaction that occurred on Tuesday, June 20th. The shares were sold at an average price of GBX 1,693 ($21.86), for a total value of £81,602.60 ($105,388.87). Also, insider Patrick Vallance bought 861 shares of the company’s stock in a transaction dated Friday, July 14th. The stock was purchased at an average cost of GBX 1,618 ($20.90) per share, for a total transaction of £13,930.98 ($17,991.71). Over the last three months, insiders bought 3,152 shares of company stock worth $5,055,023.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.